In a 62-year-old female who is now asymptomatic after an emergency department visit for a small pulmonary embolism identified on chest CT angiography, should I obtain C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR), and what additional laboratory or imaging studies are indicated?

No, do not order CRP or ESR for pulmonary embolism management

CRP and ESR are not indicated in the routine workup or follow-up of pulmonary embolism—these inflammatory markers have no role in PE diagnosis, risk stratification, or treatment decisions. 1

Why CRP and ESR Are Not Helpful

The evidence is clear that these tests serve no purpose in PE management:

• CRP cannot safely exclude PE: Even when combined with clinical probability assessment, CRP showed only 84% sensitivity with a negative predictive value of 87%—far below the safety threshold needed for PE exclusion 2

• ESR is frequently misleading: In hospital practice, ESR shows poor agreement with CRP (kappa=0.38) and is confounded by age, anemia, renal function, and other non-inflammatory factors. In one study, 28% of elevated ESR values were false positives due to interfering variables 3

• Neither marker guides PE treatment: Current ESC and CHEST guidelines make no mention of inflammatory markers for PE management, risk stratification, or anticoagulation decisions 1, 4

What You Actually Need to Order

Based on established guidelines, here's what is indicated for your patient:

Essential Follow-up Testing

Echocardiography (which you already ordered) is appropriate to:

• Assess right ventricular function
• Evaluate for pulmonary hypertension
• Establish baseline cardiac function 1

Additional Laboratory Studies to Consider

Baseline labs before extended anticoagulation:

• Complete blood count (assess bleeding risk, baseline hemoglobin)
• Renal function (creatinine/eGFR—critical for DOAC dosing and monitoring)
• Hepatic function (baseline liver enzymes)
• Pregnancy test if applicable (NOACs contraindicated in pregnancy) 1

Risk Factor Assessment

Consider testing for thrombophilia only if:

• She has recurrent unprovoked VTE
• Strong family history of VTE
• Unusual clot location
• Do NOT routinely screen for thrombophilia after first PE as it rarely changes management 1

Anticoagulation Management

The key clinical decisions now are:

1. Duration of anticoagulation:

   • If this PE was provoked by a major transient risk factor (surgery, trauma, immobilization), discontinue after 3 months 1
   • If unprovoked, consider extended anticoagulation beyond 3 months with regular reassessment 1

2. Regular monitoring intervals should assess:

   • Drug tolerance and adherence
   • Renal and hepatic function
   • Bleeding risk 1

Follow-up Imaging

Routine re-evaluation at 3-6 months after acute PE is recommended to:

• Assess for persistent symptoms
• Screen for chronic thromboembolic pulmonary hypertension (CTEPH)
• Consider V/Q scan if symptomatic with mismatched perfusion defects 1

Common Pitfall to Avoid

The most common error is ordering inflammatory markers reflexively when following up cardiopulmonary findings. CRP and ESR would only be relevant if you suspected an alternative inflammatory diagnosis (pericarditis, vasculitis, infection)—but you've already confirmed PE on CTA, and she's now asymptomatic. These tests would add no value and potentially create confusion with false-positive elevations from age, obesity, or other non-inflammatory factors 3, 5.